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S U M M A R Y
The detection of acute human immunodeﬁciency virus (HIV), hepatitis B virus (HBV), and hepatitis C
virus (HCV) infection is vital for controlling the spread of HIV, HBV, and HCV to uninfected individuals.
Considering that these viruses have high replication rates and are undetectable by serological markers,
early detection upon transmission is crucial. Various nucleic acid assays have been developed for
diagnostics and therapeutic monitoring of infections. In the past decade, rapid and sensitive molecular
techniques such as PCR have revolutionized the detection of a variety of infectious viruses, including HIV,
HCV, and HBV. Here, we describe two of the most commonly used licensed methods for the detection and
quantiﬁcation of HIV, HCV, and HBV: the cobas TaqScreen MPX (PCR) test and the Tigris System. We used
transcription-mediated ampliﬁcation to review and compare the development and efﬁciency of these
technologies.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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The quality and safety of blood products used in transfusions are
major public health concerns. In addition to general quality control
(QC), the introduction of good manufacturing practices and routine
screening of blood materials and products, has ensured consistency,
quality, and safety in the increased production and use of blood
products in recent decades. Newly developed serological tests and
nucleic acid tests (NATs) have markedly reduced the risk of
transmission of human immunodeﬁciency virus (HIV), hepatitis C
virus (HCV), and hepatitis B virus (HBV).1 In the past decade, rapid
and sensitive molecular techniques such as PCR have revolutionized
the detection of a variety of infectious viruses.2–4
About 10 years ago, molecular methods achieved a signiﬁcant
level of throughput and automation, enabling their introduction as
an additional tool in blood screening. The aim of these tests was
primarily to prevent donations made during the window-period
from being used in transfusions.5,6 An international survey7
reported ﬁndings from the use of NATs in 330 million blood
donations and showed overall infection rates of 1:447 000 for HCV,* Corresponding author. Tel.: +55 11 993647519; fax: +55 11 50556588.
E-mail address: gui.albertoni@uol.com.br (G. Albertoni).
http://dx.doi.org/10.1016/j.ijid.2014.04.007
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1:111 000 for HIV, and 1:66 000 for HBV. Up until 2011, very few of
Brazil’s blood banks (corresponding to less than 5% of the national
blood supply) had voluntarily introduced NAT screening. More
recently, an HCV/HIV NAT kit was developed by Bio-Manguinhos/
Fiocruz (Rio de Janeiro, Brazil). This test is now used in some of
Brazil’s large public blood banks and is expected to be extended to
all public blood banks, when the test may become mandatory.8
In this article, we describe two of the most commonly used
licensed molecular methods for the detection and quantiﬁcation of
HIV, HCV, and HBV in blood. We compared the lower limits of virus
detection of each method and evaluated the overall performance.
2. Nucleic acid testing (NAT)
The World Health Organization (WHO) recommends that
diagnostic devices are ‘ASSURED’: Affordable, Sensitive, Speciﬁc,
User-friendly, Rapid and Robust, Equipment-free, and Deliver-
able to end users, especially with regard to developing countries.
Nucleic acid ampliﬁcation techniques (NAATs), however,
typically require a signiﬁcant investment in equipment, training,
and infrastructure. Nevertheless, the development of these
molecular techniques as diagnostic tools has become increasingly
important.9–13ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Standard curve of the HIV RNA concentration (IU/ml) (slope: 3.20; R2:
0.99).
Figure 2. Standard curve of the HBV DNA concentration (IU/ml) (slope: 2.75; R2:
0.98).
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The fact that PCR reactions can be monitored in real time has
revolutionized the process of DNA and RNA fragment quantiﬁ-
cation. Nucleic acid quantiﬁcation using quantitative real-time
PCR (qRT-PCR) is extremely accurate and reproducible. In
qRT-PCR, each round of ampliﬁcation leads to the emission of
a ﬂuorescent signal, and the number of signals per cycle is
proportional to the amount of target nucleic acid in the starting
sample.14 This allows for accurate and reproducible quantiﬁca-
tion based on ﬂuorescence. The most commonly used ﬂuorescent
compounds in qRT-PCR are the SYBR Green dye and the TaqMan
probe.14 qRT-PCR requires an instrumentation platform that
consists of a thermal cycler, a computer, optics for ﬂuorescence
excitation and emission collection, and data acquisition and
analysis software.14–16
2.2. In-house NAT for HCV detection
For the detection and quantiﬁcation of HCV RNA,17 we designed
and developed a one-step NAT TaqMan qRT-PCR method.
Using international standards (ACCURUN HCV RNA Positive
Control; SeraCare) containing 3  105 IU/ml of HCV RNA (1 U = 1–3
copies),14 our NAT in-house qRT-PCR TaqMan HCV assay
displayed linearity over a range of 3.1  102 to 3.1  105 IU/ml
(2.5–5.5 log). The lower limit of detection of the method was 310
IU/ml. In a previous report by Wendel et al., 18 the method used to
screen blood donors by NAT testing for HCV RNA displayed
linearity over a range of 5  102 to 5  104. The lower limit of
detection of the method was 500 IU/ml. In another study, Paryan
et al.19 designed and developed an in-house multiplex RT-PCR
assay for the detection of HCV in plasma samples. That multiplex
assay was linear between 102 and 105 copies/ml (six of eight
samples were detectable), and had an analytical sensitivity of
200 copies/ml.
2.3. In-house NAT for HIV detection
We designed and developed a one-step TaqMan NAT qRT-PCR
method for the detection of HIV RNA.20
We recently developed a NAT TaqMan qRT-PCR HIV RNA assay
using a set of international standards (AcroMetrix HIV-1 Panel IU/
ml RNA Positive Control; Applied Biosystems) containing 1  102
to 1  107 IU/ml of HIV RNA. Each panel member (except the
negative control) contains HIV-1 at a predetermined concentration
calibrated against the WHO international standard for HIV-1 RNA.
Consequently, the assigned values are reported in international
units per milliliter (IU/ml). Some studies have reported results in
units that differ from the international units as deﬁned by the
WHO.21 For our in-house NAT TaqMan qRT-PCR HIV assay, we
observed linearity over a range of 1  102 to 1  107 IU/ml and a
lower limit of detection of 100 IU/ml (Figure 1). Similarly, Paryan
et al.,19 using multiplex RT-PCR, showed linearity over a range of 1
 102 to 1  105 copies/ml and an analytical sensitivity of 100
copies/ml for HIV RNA. In experiments by De Crignis et al.,22 a SYBR
Green I Multiplex RT-PCR was successfully used to detect HIV RNA,
and was found to have an analytical sensitivity of 400 copies/ml for
HIV RNA.
2.4. In-house NAT for HBV detection
We developed a NAT in-house qRT-PCR TaqMan HBV DNA assay
using international standards (AcroMetrix HBV Panel IU/ml DNA
Positive Control; Applied Biosystems) containing 2  102 to 2  107
IU/ml of HBV DNA. Our HBV assay displayed linearity over a range
of 2  102 to 2  107 IU/ml, and the lower limit of detection of themethod was 200 IU/ml (Figure 2). dos Santos et al.23 developed a
cost-effective RT-PCR test to detect a wide range of HBV DNA in the
western mazonas region. Their method displayed linearity over a
range of 2  103 to 2  109 copies/ml and a lower limit of detection
of 2000 IU/ml. Yalamanchili et al.24 designed a rapid, reliable, and
sensitive assay for the detection of HBV by RT-PCR. The calibration
curve was linear over a range of 1  102 to 1  108 copies/ml, with
an R2 value of 0.999. The lower limit of detection of the method was
100 copies/ml.
3. Current approaches
Several US Food and Drug Administration (FDA)-licensed NAT
assays are currently available for the screening of blood donors for
HIV, HCV, HBV, and West Nile virus (WNV). The continued
development of highly sensitive screening NAT systems, however,
is challenging.25 The FDA has licensed several triplex (HIV/HCV/
HBV) automated NAT systems for blood donor screening.26 These
include the PCR-based cobas TaqScreen MPX assay using the cobas
s 201 instrument (Roche Diagnostics GmbH, Mannheim,
Germany), and the Procleix Ultrio assay, using the Procleix Tigris
automated instrument (Novartis Diagnostics, Emeryville, CA, USA/
Gen-Probe, San Diego, CA, USA) and employing transcription-
mediated ampliﬁcation (TMA).27–30
3.1. PCR-based cobas TaqScreen MPX test
The cobas TaqScreen MPX test is a multiplex, multi-dye nucleic
acid ampliﬁcation technology. Sample nucleic acids and armored
RNA internal control (IC) molecules, which serve as specimen
preparation and ampliﬁcation/detection process controls, are
processed simultaneously. A protease solution digests proteins
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RNA and DNA from viral particles. The released nucleic acids bind
to the silica surface of magnetic glass particles, which are added to
the reaction mixture. The binding of nucleic acids to the particles is
mainly due to the net positive charge on the glass particle surface
and net negative charge of the nucleic acids at the chaotropic salt
concentration and ionic strength of the lysis reaction. A wash
reagent removes unbound substances and impurities. Using an
elution buffer, puriﬁed nucleic acids are then released from the
magnetic glass particles at high temperatures.31
After isolation of the puriﬁed nucleic acids from human plasma,
cobas TaqScreen Master Mix (MPX MMX) is used for the
ampliﬁcation and detection of HIV-1 (groups M and O), HIV-2,
and HCV RNA, as well as HBV DNA and IC RNA. Once the MPX MMX
is activated by the addition of manganese acetate, reverse
transcription (for RNA targets) proceeds, followed by PCR
ampliﬁcation of highly conserved regions of HIV-1 (groups M
and O), HIV-2, and HCV RNA, as well as HBV DNA and IC RNA using
speciﬁc primers.31
Simultaneous detection of the ampliﬁed nucleic acids is
accomplished by the generation of ﬂuorescent signals from 50-
nucleolytic degradation of HIV-1- (groups M and O), HIV-2-, HCV-,
HBV- and IC-speciﬁc probes. Two ﬂuorescent dyes are used, one
labeling the IC probe and a second labeling all target-speciﬁc
probes, allowing for the combined identiﬁcation of each viral
target as well as independent identiﬁcation of the IC. Reverse
transcription and ampliﬁcation reactions are performed with a
thermostable recombinant DNA polymerase enzyme. In the
presence of manganese (Mn2+), DNA polymerase has reverse
transcriptase and DNA polymerase activities. This allows both
reverse transcription and PCR ampliﬁcation to occur in the same
reaction mixture.31
Selective ampliﬁcation of target nucleic acid from the specimen
is achieved by the use of a uracil-N-glycosylase enzyme and
deoxyuridine triphosphate. The enzyme recognizes and catalyzes
the destruction of DNA strands containing deoxyuridine,32 but not
DNA containing deoxythymidine or RNA containing ribouri-
dine.33,34
During PCR ampliﬁcation, the intermittent high temperatures
during thermal cycling denature target and IC amplicons to form
single-stranded DNA. The speciﬁc oligonucleotide probes, which
facilitate signal detection, hybridize to the single-stranded form of
the ampliﬁed DNA, and ampliﬁcation, hybridization, and detection
occur simultaneously.33,35,36 During PCR ampliﬁcation, probes
hybridize to speciﬁc single-stranded DNA sequences and are
cleaved by the 50 to 30 nuclease activity of the DNA polymerase
while ampliﬁcation is occurring. Once the reporter and quencher
dyes are separated by this cleavage, the ﬂuorescent activity of the
reporter dye is unmasked. With each PCR cycle, increasing
amounts of cleaved probes are generated and the cumulative
signal of the reporter dye is concomitantly increased.35,36 Real-
time detection of PCR products is accomplished by measuring the
ﬂuorescence of released reporter dyes representing the viral
targets.35,36
3.2. Published studies that have used the cobas PCR NAT system
In a recent study, Mu¨ller et al.26 used a commercial, multi-dye
nucleic acid ampliﬁcation technology test for HBV/HCV and HIV-1/
2 to assess the analytical sensitivity of the test in samples
containing low concentrations of each virus. The study describes
the evaluation of the MPX v2 test by two blood banks in Europe:
the German Red Cross Blood Donor Service (Frankfurt, Germany)
and the Centro de Hemoterapia y Hemodonacı´on de Castilla y Leo´n
(Valladolid, Spain). The analytical sensitivities of the MPX v2 test
determined by the German and Spanish blood banks were 1.1 and3.5 IU/ml for HBV, 3.9 and 17.6 IU/ml for HCV, and 43.3 and 50.6 IU/
ml for HIV-1, respectively.26
In another study, Roche37 reported on the analytical sensitivi-
ties of two versions of the MPX test (MPX v1 and MPX v2) in the
detection of HBV, HCV, and HIV-1. In the case of the current
commercial NAT test – the MPX v1 test – a reactive sample has to
be tested further with three individual, virus-speciﬁc NAT tests in
order to identify the viral contamination. One of the major
disadvantages of this strategy is that a conﬁrmed reactive sample is
often non-reactive when tested with discriminatory tests.38–40
This discrepancy is most likely to occur with samples containing
low viral loads, typically samples from donors with occult HBV
infection.39 The MPX v2 test that was evaluated in this study was
the ﬁrst commercial multiplex test able to simultaneously detect
and identify viral contaminants in plasma samples. The MPX v2
test thus eliminates the drawbacks of the previous version of the
test.26 The lower limits of detection (IU/ml) of the MPX v1 test were
3.8, 11.0, and 49.0 for HBV, HCV, and HIV-1, respectively, and in the
case of the MPX v2 test, the limits were 2.3, 6.8, and 46.2 for HBV,
HCV, and HIV-1, respectively.37,41 Previous studies42,43 found the
MPX v1 test to be more sensitive for HBV than for HCV, and
although it appears that the analytical sensitivity of the Ultrio test
is more sensitive than the MPX tests for HIV-1, the two studies that
have directly compared the methods43,44 reported these differ-
ences between the Ultrio and MPX v1 tests not to be signiﬁcant.
Similarly, the analytical sensitivities of the German Red Cross kits
for HBV and HIV-1 detection appear to be signiﬁcantly more
sensitive than those of the MPX v2 test; however, the limited
clinical research comparing the two tests showed no difference in
clinical performance.26
The performance of the MPX v2 test for routine donor samples
was compared with the tests on record at the two blood banks.26 In
the latter case, an HBV-positive sample was not detected with the
test on record, which was the MPX v1 test, although the analytical
sensitivities of the MPX v1 and MPX v2 tests are very similar (95%
limit of detection of 3.8 and 2.3 IU/ml, respectively).26 One
explanation for this could be that the donor in this case was a
chronic HBV carrier with a low HBV titer that was detected
intermittently.39 The performance of the MPX v2 test for testing
routine donor samples was comparable to both of the in-house tests
of the German Red Cross Blood donor Service and the MPX v1 test at
Centro de Hemoterapia y Hemodonacı´on de Castilla y Leo´n.26
Stramer et al.30 provide a summary of HBV DNA analytical
sensitivities of commercially available triplex NAT assays. These
data are limited to those studies using well-characterized WHO
stock preparations. HBV DNA analytical sensitivity at a 95% limit of
detection is approximately 4 IU/ml (range 3–8 IU/ml), and HVC and
HIV analytical sensitivities (95% limit of detection) are approxi-
mately 7–22 IU/m and 42–58 IU/ml, respectively.
3.3. Procleix Ultrio assay: TMA
The state-of-the-art TMA technology used in the Procleix Ultrio
assay was developed by Gen-Probe, Inc. (San Diego, CA, USA), our
partner for NAT innovation. The assay makes use of the Procleix
Tigris System, which is a fully automated system for nucleic acid
ampliﬁcation and detection based on TMA technology.
The Procleix Ultrio assay procedure consists of three main
steps: target capture, ampliﬁcation, and detection. During target
capture, samples are prepared for testing by virus lysis to release
the genetic material. No pretreatment or sample handling is
required. Capture probes hybridize with IC and viral nucleic acids
and bind them to magnetic particles. Unbound, non-speciﬁc
material is removed by washing to minimize potential inhibitors.
RNA and/or DNA ampliﬁcation in the Procleix Ultrio assay occurs
via TMA. Reverse transcriptase creates a DNA copy (cDNA) of the
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synthesizing RNA from the cDNA. Some of the newly synthesized
RNA ampliﬁcation products reenter the TMA process and serve as
templates for new rounds of ampliﬁcation. Billions of copies can
potentially be generated in less than an hour.43 Detection follows
on from the ampliﬁcation step. Acridinium ester (AE)-labeled
probes speciﬁcally hybridize to ampliﬁcation products. Different
AE variants are used to label IC- and viral-speciﬁc probes. The
hybridization protection assay (HPA) process selectively inacti-
vates the AE labels on unhybridized probes to minimize
background signal, and dual kinetic assay (DKA) technology allows
for the simultaneous detection of both IC-encoded and viral-
encoded RNA by the detection of a brief ﬂash of light and a longer-
lasting glow, respectively, produced by the RNA.43
3.4. Published literature on TMA-based NATs
A new version of the TMA assay, Ultrio Plus, was recently
launched in the European Union (EU), and we were interested to
know whether this new version of the assay has improved sensitivity
in detecting low viral load HBV compared with the original assay. In
comparison to the original Ultrio assay, the Ultrio Plus assay includes
an additional reagent that contains concentrated lithium hydroxide,
which enhances the disruption of HBV particles and the subsequent
release of DNA for the capture probe to target.
Grabarczyk et al.4 reported on a direct comparison of the two
TMA assays for the detection of HBV, HCV, and HIV in blood donors.
The analytical sensitivities of the Ultrio and Ultrio Plus assays were
analyzed using dilution panels of WHO international standards
with the following concentrations: WHO HBV genotype A: 50, 15,
5, 1.5, 0.5, 0.15, and 0.05 IU/ml; WHO HCV subtype 1: 100, 30, 10, 3,
1, 0.3, and 0.1 IU/ml; and WHO HIV-1 subtype B: 600, 200, 60, 20, 6,
2, and 0.6 IU/ml. A comparison of the 50% and 95% limits of
detection by probit analysis in parallel line mode showed the two
versions of the TMA assays to have equal analytical sensitivity to
the WHO HCV and HIV-1 standards, but in the case of HBV, the
Ultrio Plus assay was found to have a 2.4-fold higher sensitivity
than the Ultrio assay.4 The assessment of the analytical sensitivi-
ties of the two assays showed the 95% limits of detection for HBV
DNA, HCV RNA, and HIV-1 RNA to be 11.1, 9.0, and 14.2 IU/ml,
respectively, for the Ultrio assay, and 4.6, 9.3, and 18.5 IU/ml,
respectively, for the Ultrio Plus assay.4
Stramer et al.42 carried out a comparative study of triplex NAT
assays in the USA. The results of the study showed the 95% limit of
detection of HBV DNA to be 10–15 IU/ml (95% range, 8–40 IU/ml) in
the Ultrio assay and 2–4 IU/ml (95% range, 2–10 IU/ml) for the
Ultrio Plus assay. The Ultrio Plus assay was thus more sensitive for
HBV DNA detection than the Ultrio assay. According to studies
reported on in the product package inserts, the HCV analytical
sensitivities for the two assays are equal (2–6 IU/ml), as are the
HIV-1 analytical sensitivities (16–40 IU/ml).
In a comparative study evaluating triplex NATs for the detection
of HBV DNA, HCV RNA, and HIV-1 RNA by Xiao et al.,43 the Procleix
Tigris System often detected HBV at viral levels below 50 IU/ml.
Whereas the HBV viral loads in the chronic donations were close to
the NAT cut-off (approximately 15 IU/ml for the Procleix Ultrio
assay).44
4. Discussion
Fully automated triplex (HIV, HCV, and HBV) NAT assays have
been available in the USA since 2007, and guidelines regarding the
requirements for HIV-1 and HCV NAT assays were issued in 2010.45
In November 2012, the FDA issued guidelines regarding HBV DNA
detection NAT assays, stipulating that such assays should have a
minimum sensitivity of 100 IU/ml (approximately 500 copies/ml).46The main advantage of the MPX v2 test over other licensed
blood screening NATs currently being used, is its ability to
simultaneously detect and identify the viral target in a sample. The
need for supplementary viral target discriminatory tests is
eliminated in this assay, as are the associated training require-
ments. Multiplex, multi-dye tests also reduce the required sample
volumes, which is important in an environment in which the
number of viral agents being tested for by NATs has gradually
increased over the last few years.26 The MPX v2 test is currently
limited to four channels and dyes, one of which is used for the IC.
Consequently, all HIV viruses (HIV-1 groups M and O and HIV-2)
are detected in a single channel, and thus further testing is
required.26 The Roche MPX test carried out on the s 201 platform
represents an improved and fully automated NAT blood and
plasma screening system.26 As shown in our results, this
technology proved to be highly sensitive compared with the
technologies developed in-house in our group.17,20
The analytical sensitivity studies on the Ultrio and Ultrio Plus
assay systems showed that the two TMA assays are equally
sensitive for the detection of HCV and HIV-1. However, the
inclusion of an alkaline shock step to the virus particle during the
target capture process has signiﬁcantly improved the analytical
sensitivity of the assay to HBV in the Ultrio Plus assay. The NAT
efﬁciency in both TMA assay versions appears to be optimal for
HCV and HIV-1. The detection efﬁciency of the original Ultrio assay
for HBV DNA, however, was poor, and ranged from 2% to 43%. This
range was increased to 18% to 81% by improved target capture
chemistry in the Ultrio Plus assay.4 One explanation for this is that
the improvement offered by the alkaline shock depends largely on
the length of the double-stranded (ds) DNA portion of the HBV
genome.4 This dsDNA portion varies even within one carrier,47 and
may be even more variable between individuals infected with
different HBV variants. It is thus possible that denaturation of
dsDNA is an additional contributing factor to the enhanced
sensitivity of the Ultrio Plus assay, and that the remaining
variability in limits of detection in the Ultrio Plus assay is a
reﬂection of incomplete denaturation of dsDNA during target
capture. Another explanation for the higher detection efﬁciency of
the Ultrio Plus assay for HBV is the denaturation of a tightly
attached protein to the HBV genome47 that otherwise could inhibit
target capture by steric hindrance. Such an inhibitory effect by
interfering proteins does not play a role in capturing HIV RNA and
HCV RNA, which may explain why the NAT efﬁciencies for these
viruses are found to be higher than that for HBV. Regardless of the
explanation, the alkaline shock step has certainly contributed to an
enhanced sensitivity in the Ultrio Plus assay.
The results of a comparative study of the Ultrio and Ultrio Plus
assays showed that there was no difference in the analytical
sensitivities of the two assays to HCV and HIV-1, but that the Ultrio
Plus assay had a three-fold higher sensitivity to HBV than the Ultrio
assay.
5. Conclusions
Although the introduction of real-time PCR has led to
considerable progress in automating the ampliﬁcation and
detection steps of NATs, nucleic acid isolation remains very
labor-intensive when performed manually. Traditional phenol–
chloroform extraction and ethanol precipitation methods are
complicated, time-consuming, hazardous, and unsuitable for
processing high numbers of samples.
Some technical problems of ‘in-house’ nucleic acid ampliﬁca-
tion technology for detection purposes are recognized widely,
especially: (1) manual extraction of nucleic acids, enabling the loss
of RNA or DNA; (2) low sensitivity of the ampliﬁcation reaction; (3)
optimal ampliﬁcation design and thorough optimization of the
G. Albertoni et al. / International Journal of Infectious Diseases 25 (2014) 145–149 149ampliﬁcation conditions; (4) a reproducible quantitative ampliﬁ-
cation assay is very difﬁcult to construct and it remains laborious
and cumbersome. Thus, the automation of nucleic acid extraction
and ampliﬁcation technology becomes necessary.
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